Healthcare Industry News: INOmax
News Release - October 1, 2007
Ikaria Names Executive Vice President of Research and DevelopmentCLINTON, N.J., Oct. 1 (HSMN NewsFeed) -- Ikaria Holdings, Inc. announced today that Ralf Rosskamp, M.D., has been appointed Executive Vice President of Research and Development, reporting to Chairman and CEO David Shaw.
Dr. Rosskamp most recently was Executive Vice President of R&D at Kos Pharmaceuticals. Prior to joining Kos, Ralf was Vice President of Global Therapeutic R&D for Endocrinology, Metabolism, Rheumatology and Bone at Aventis Pharmaceuticals. Earlier in his career he held executive positions at Hoechst Pharmaceuticals and served as a senior physician in the Department of Pediatrics at the University of Bonn (Germany), where he earned his M.D.
"Ralf has extensive experience in a wide range of important drug development activities, including clinical research, regulatory affairs, clinical pharmacology, aerosol and solid dose R&D, biomedical engineering, pharmacovigilance, medical affairs and project/portfolio management," stated Mr. Shaw. "He has been very successful in managing pharmaceutical R&D efforts in both large and small companies. We expect Ikaria to benefit significantly from his knowledge, experience and leadership as we build a leading company in critical care medicine."
About Ikaria Holdings
Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations that improve the lives of patients. The company's INOmax product (inhaled nitric oxide) is an FDA-approved drug for the treatment of pulmonary hypertension in newborns, and is extensively used in critical settings in the United States, Canada, Europe, Latin America and Asia. Ikaria has a staff of over 300 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information, please visit the company's web site at http://www.ikaria.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.